1
|
Joy BK, Donovan AL, McCracken GR, Pettipas J, Grudeski E, Majer A, Mandes R, Booth TF, Hatchette TF, Patriquin G, LeBlanc JJ. Hunting for mpox (monkeypox) mimickers: Use of the Biofire meningitis/encephalitis panel on lesion swabs to support alternative viral diagnoses. J Clin Virol 2023; 159:105356. [PMID: 36608619 PMCID: PMC9789924 DOI: 10.1016/j.jcv.2022.105356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2022] [Revised: 12/08/2022] [Accepted: 12/18/2022] [Indexed: 12/26/2022]
Abstract
BACKGROUND Mpox (formerly monkeypox) is an emerging zoonotic disease of public health concern that presents as a rash mimicking other common viral exanthems. Unlike traditional testing algorithms relying on several assays, the BioFire FilmArray meningitis/encephalitis (ME) panel simultaneously detects common viruses causing rashes; however, Biofire ME is only licensed for testing on cerebral spinal fluid. OBJECTIVES This study evaluated use of the Biofire ME panel for detection and discrimination of herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), varicella zoster virus (VZV), human herpesviruses type 6 (HHV-6), enteroviruses (EVs), and human paraechoviruses (HPeVs) from a dermal or mucocutaneous swabs collected in universal transport media (UTM). STUDY DESIGN Results of the BioFire ME panel were compared against methods used during clinical testing. Ten-fold serial dilutions in UTM of cultured viruses were used to compare analytical sensitivity, and analytical specificity was assessed using panels of microorganisms in UTM. Clinical sensitivity and specificity were assessed using 20 positive specimens each for HHV-1, HHV-2, HHV-6, VZV, EVs, and HPeV, as well as 35 known negative specimens that included 15 mpox-positive specimens. RESULTS Biofire ME was as sensitive as comparator methods, and correctly discriminated all HSV-1, HSV-2, VZV, HHV-6, EVs, and HPeVs from mpox and mpox-mimickers. Cross-reaction between EV and rhinoviruses A, B, and C were noted in the specificity panel. CONCLUSIONS Swabs in UTM collected for mpox testing are suitable for use on the Biofire ME panel, allowing more streamlined diagnostic testing for viral exanthems in patients under investigation for mpox infection.
Collapse
Affiliation(s)
- Bryn K. Joy
- Medical Sciences Program, Faculty of Sciences, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Alexis L. Donovan
- School of Medicine, Royal College of Surgeons in Ireland (RSCI) University of Medicine and Health Sciences, Dublin, Ireland
| | - Gregory R. McCracken
- Division of Microbiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health, Halifax, Nova Scotia, Canada
| | - Janice Pettipas
- Nova Scotia Provincial Public Health Laboratory Network (PPHLN), Halifax, Nova Scotia, Canada
| | - Elsie Grudeski
- Enteroviruses and Enteric Viruses Laboratory, National Microbiology Laboratory (NML), Winnipeg, Manitoba, Canada
| | - Anna Majer
- Enteroviruses and Enteric Viruses Laboratory, National Microbiology Laboratory (NML), Winnipeg, Manitoba, Canada
| | - Russell Mandes
- Enteroviruses and Enteric Viruses Laboratory, National Microbiology Laboratory (NML), Winnipeg, Manitoba, Canada
| | - Tim F. Booth
- Enteroviruses and Enteric Viruses Laboratory, National Microbiology Laboratory (NML), Winnipeg, Manitoba, Canada
| | - Todd F. Hatchette
- Division of Microbiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health, Halifax, Nova Scotia, Canada,Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada,Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.,Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Glenn Patriquin
- Division of Microbiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health, Halifax, Nova Scotia, Canada,Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Jason J. LeBlanc
- Division of Microbiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health, Halifax, Nova Scotia, Canada,Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada,Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.,Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.,Corresponding author at: Division of Microbiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health (NSH), Room 404B, MacKenzie Building, 5788 University Avenue, Halifax, Nova Scotia, B3H 1V8, Canada
| |
Collapse
|
2
|
Tadesse LF, Safir F, Ho CS, Hasbach X, Khuri-Yakub BP, Jeffrey SS, Saleh AAE, Dionne J. Toward rapid infectious disease diagnosis with advances in surface-enhanced Raman spectroscopy. J Chem Phys 2021; 152:240902. [PMID: 32610995 DOI: 10.1063/1.5142767] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
In a pandemic era, rapid infectious disease diagnosis is essential. Surface-enhanced Raman spectroscopy (SERS) promises sensitive and specific diagnosis including rapid point-of-care detection and drug susceptibility testing. SERS utilizes inelastic light scattering arising from the interaction of incident photons with molecular vibrations, enhanced by orders of magnitude with resonant metallic or dielectric nanostructures. While SERS provides a spectral fingerprint of the sample, clinical translation is lagged due to challenges in consistency of spectral enhancement, complexity in spectral interpretation, insufficient specificity and sensitivity, and inefficient workflow from patient sample collection to spectral acquisition. Here, we highlight the recent, complementary advances that address these shortcomings, including (1) design of label-free SERS substrates and data processing algorithms that improve spectral signal and interpretability, essential for broad pathogen screening assays; (2) development of new capture and affinity agents, such as aptamers and polymers, critical for determining the presence or absence of particular pathogens; and (3) microfluidic and bioprinting platforms for efficient clinical sample processing. We also describe the development of low-cost, point-of-care, optical SERS hardware. Our paper focuses on SERS for viral and bacterial detection, in hopes of accelerating infectious disease diagnosis, monitoring, and vaccine development. With advances in SERS substrates, machine learning, and microfluidics and bioprinting, the specificity, sensitivity, and speed of SERS can be readily translated from laboratory bench to patient bedside, accelerating point-of-care diagnosis, personalized medicine, and precision health.
Collapse
Affiliation(s)
- Loza F Tadesse
- Department of Bioengineering, Stanford University School of Medicine and School of Engineering, Stanford, California 94305, USA
| | - Fareeha Safir
- Department of Mechanical Engineering, Stanford University School of Engineering, Stanford, California 94305, USA
| | - Chi-Sing Ho
- Department of Applied Physics, Stanford University School of Humanities and Sciences, Stanford, California 94305, USA
| | - Ximena Hasbach
- Department of Materials Science and Engineering, Stanford University School of Engineering, Stanford, California 94305, USA
| | - Butrus Pierre Khuri-Yakub
- Department of Electrical Engineering, Stanford University School of Engineering, Stanford, California 94305, USA
| | - Stefanie S Jeffrey
- Department of Surgery, Stanford University School of Medicine, Stanford, California 94305, USA
| | - Amr A E Saleh
- Department of Materials Science and Engineering, Stanford University School of Engineering, Stanford, California 94305, USA
| | - Jennifer Dionne
- Department of Materials Science and Engineering, Stanford University School of Engineering, Stanford, California 94305, USA
| |
Collapse
|
3
|
Zalzala H. Diagnosis of COVID-19: facts and challenges. New Microbes New Infect 2020; 38:100761. [PMID: 32953123 PMCID: PMC7492157 DOI: 10.1016/j.nmni.2020.100761] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2020] [Revised: 09/07/2020] [Accepted: 09/11/2020] [Indexed: 12/23/2022] Open
Abstract
At the end of 2019, the novel coronavirus disease 2019 (COVID-19) emerged in Wuhan, China, then spread rapidly across the country and throughout the world. The causative agent is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); according to the International Committee on Taxonomy of Viruses, this virus has a nucleic acid sequence that is different from other known coronaviruses but has some similarity to the beta coronavirus identified in bats. Coronaviruses are a large virus group of enveloped positive-sense single-stranded RNA. They are divided into four genera-alpha, beta, delta and gamma-and alpha and beta coronaviruses are known to infect humans. Rapid and early diagnosis of COVID-19 is a challenging issue for physicians and other healthcare personnel. The sensitivity and specificity of the clinical, radiologic and laboratory tests used to diagnose COVID-19 are variable and largely differ in efficacy depending on the disease's stage of presentation.
Collapse
Affiliation(s)
- H.H. Zalzala
- Department of Microbiology and Immunology, HLA Typing Research Unit, University of Baghdad, Al-Kindy College of Medicine, Baghdad, Iraq
| |
Collapse
|
4
|
LeBlanc JJ, Gubbay JB, Li Y, Needle R, Arneson SR, Marcino D, Charest H, Desnoyers G, Dust K, Fattouh R, Garceau R, German G, Hatchette TF, Kozak RA, Krajden M, Kuschak T, Lang ALS, Levett P, Mazzulli T, McDonald R, Mubareka S, Prystajecky N, Rutherford C, Smieja M, Yu Y, Zahariadis G, Zelyas N, Bastien N. Real-time PCR-based SARS-CoV-2 detection in Canadian laboratories. J Clin Virol 2020; 128:104433. [PMID: 32405254 PMCID: PMC7219382 DOI: 10.1016/j.jcv.2020.104433] [Citation(s) in RCA: 85] [Impact Index Per Article: 21.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2020] [Accepted: 05/09/2020] [Indexed: 12/21/2022]
Abstract
With emergence of pandemic COVID-19, rapid and accurate diagnostic testing is essential. This study compared laboratory-developed tests (LDTs) used for the detection of SARS-CoV-2 in Canadian hospital and public health laboratories, and some commercially available real-time RT-PCR assays. Overall, analytical sensitivities were equivalent between LDTs and most commercially available methods.
Collapse
Affiliation(s)
- Jason J LeBlanc
- Division of Microbiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health Authority (NSHA), Room 404B, MacKenzie Building, 5788 University Avenue, Halifax, Nova Scotia B3H 1V8, Canada; Departments of Pathology, Medicine, and Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.
| | - Jonathan B Gubbay
- Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Public Health Ontario Laboratories, Toronto, Ontario, Canada; Hospital for Sick Children, Toronto, Ontario, Canada
| | - Yan Li
- National Microbiology Laboratory (NML), Public Health Agency of Canada (PHAC), Winnipeg, Manitoba, Canada
| | - Robert Needle
- Public Health and Microbiology Laboratory, St. John's, Newfoundland, Canada
| | - Sandra Radons Arneson
- National Microbiology Laboratory (NML), Public Health Agency of Canada (PHAC), Winnipeg, Manitoba, Canada
| | - Dionne Marcino
- National Microbiology Laboratory (NML), Public Health Agency of Canada (PHAC), Winnipeg, Manitoba, Canada
| | - Hugues Charest
- Laboratoire De Santé Publique Du Québec/INSPQ, Sainte-Anne-de-Bellevue, Quebec, Canada
| | - Guillaume Desnoyers
- Centre Hospitalier Universitaire Dr. Georges L. Dumont, Moncton, New-Brunswick, Canada
| | - Kerry Dust
- Cadham Provincial Laboratory, Winnipeg, Manitoba, Canada
| | - Ramzi Fattouh
- Department of Laboratory Medicine, St. Michael's Hospital, Toronto, Ontario, Canada
| | - Richard Garceau
- Centre Hospitalier Universitaire Dr. Georges L. Dumont, Moncton, New-Brunswick, Canada
| | - Gregory German
- Queen Elizabeth Hospital, Charlottetown, Prince Edward Island, Canada
| | - Todd F Hatchette
- Division of Microbiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health Authority (NSHA), Room 404B, MacKenzie Building, 5788 University Avenue, Halifax, Nova Scotia B3H 1V8, Canada; Departments of Pathology, Medicine, and Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Robert A Kozak
- Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Sunnybrook Research Institute, Toronto, Ontario, Canada
| | - Mel Krajden
- Public Health Laboratory, British Columbia Centre for Disease Control (BCCDC), Vancouver, British Columbia, Canada
| | - Theodore Kuschak
- National Microbiology Laboratory (NML), Public Health Agency of Canada (PHAC), Winnipeg, Manitoba, Canada
| | - Amanda L S Lang
- Roy Romanow Provincial Laboratory (RRPL), Saskatchewan Health Authority (SHA), Regina, Saskatchewan, Canada
| | - Paul Levett
- Public Health Laboratory, British Columbia Centre for Disease Control (BCCDC), Vancouver, British Columbia, Canada
| | - Tony Mazzulli
- Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Department of Microbiology, Mount Sinai Hospital, Toronto, Ontario, Canada
| | - Ryan McDonald
- Roy Romanow Provincial Laboratory (RRPL), Saskatchewan Health Authority (SHA), Regina, Saskatchewan, Canada
| | - Samira Mubareka
- Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Sunnybrook Research Institute, Toronto, Ontario, Canada
| | - Natalie Prystajecky
- Public Health Laboratory, British Columbia Centre for Disease Control (BCCDC), Vancouver, British Columbia, Canada
| | | | - Marek Smieja
- St Joseph's Healthcare, Hamilton, Ontario, Canada
| | - Yang Yu
- Public Health and Microbiology Laboratory, St. John's, Newfoundland, Canada
| | - George Zahariadis
- Public Health and Microbiology Laboratory, St. John's, Newfoundland, Canada
| | - Nathan Zelyas
- Division of Microbiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health Authority (NSHA), Room 404B, MacKenzie Building, 5788 University Avenue, Halifax, Nova Scotia B3H 1V8, Canada; Provincial Laboratory for Public Health (ProvLab), Calgary, Alberta, Canada
| | - Nathalie Bastien
- National Microbiology Laboratory (NML), Public Health Agency of Canada (PHAC), Winnipeg, Manitoba, Canada
| |
Collapse
|
5
|
LeBlanc JJ, ElSherif M, Mulpuru S, Warhuus M, Ambrose A, Andrew M, Boivin G, Bowie W, Chit A, Dos Santos G, Green K, Halperin SA, Hatchette TF, Ibarguchi B, Johnstone J, Katz K, Langley JM, Lagacé-Wiens P, Loeb M, Lund A, MacKinnon-Cameron D, McCarthy A, McElhaney JE, McGeer A, Poirier A, Powis J, Richardson D, Semret M, Shinde V, Smyth D, Trottier S, Valiquette L, Webster D, Ye L, McNeil S. Validation of the Seegene RV15 multiplex PCR for the detection of influenza A subtypes and influenza B lineages during national influenza surveillance in hospitalized adults. J Med Microbiol 2020; 69:256-264. [PMID: 31264957 PMCID: PMC7431100 DOI: 10.1099/jmm.0.001032] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2019] [Accepted: 06/16/2019] [Indexed: 01/04/2023] Open
Abstract
Background. The Serious Outcomes Surveillance Network of the Canadian Immunization Research Network (CIRN SOS) has been performing active influenza surveillance since 2009 (ClinicalTrials.gov identifier: NCT01517191). Influenza A and B viruses are identified and characterized using real-time reverse-transcriptase polymerase chain reaction (RT-PCR), and multiplex testing has been performed on a subset of patients to identify other respiratory virus aetiologies. Since both methods can identify influenza A and B, a direct comparison was performed.Methods. Validated real-time RT-PCRs from the World Health Organization (WHO) to identify influenza A and B viruses, characterize influenza A viruses into the H1N1 or H3N2 subtypes and describe influenza B viruses belonging to the Yamagata or Victoria lineages. In a subset of patients, the Seeplex RV15 One-Step ACE Detection assay (RV15) kit was also used for the detection of other respiratory viruses.Results. In total, 1111 nasopharyngeal swabs were tested by RV15 and real-time RT-PCRs for influenza A and B identification and characterization. For influenza A, RV15 showed 98.0 % sensitivity, 100 % specificity and 99.7 % accuracy. The performance characteristics of RV15 were similar for influenza A subtypes H1N1 and H3N2. For influenza B, RV15 had 99.2 % sensitivity, 100 % specificity and 99.8 % accuracy, with similar assay performance being shown for both the Yamagata and Victoria lineages.Conclusions. Overall, the detection of circulating subtypes of influenza A and lineages of influenza B by RV15 was similar to detection by real-time RT-PCR. Multiplex testing with RV15 allows for a more comprehensive respiratory virus surveillance in hospitalized adults, without significantly compromising the reliability of influenza A or B virus detection.
Collapse
Affiliation(s)
- J. J. LeBlanc
- Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, and Nova Scotia Health Authority, Halifax, NS, Canada
| | - M. ElSherif
- Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, and Nova Scotia Health Authority, Halifax, NS, Canada
| | - S. Mulpuru
- Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada
| | - M. Warhuus
- Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, and Nova Scotia Health Authority, Halifax, NS, Canada
| | - A. Ambrose
- Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, and Nova Scotia Health Authority, Halifax, NS, Canada
| | - M. Andrew
- Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, and Nova Scotia Health Authority, Halifax, NS, Canada
| | - G. Boivin
- Centre Hospitalier Universitaire de Québec, QC, Canada
| | - W. Bowie
- University of British Columbia, Vancouver, BC, Canada
| | - A. Chit
- Sanofi Pasteur, Swiftwater, PA, USA
- Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
| | - G. Dos Santos
- Business & Decision Life Sciences (on behalf of GSK), Bruxelles, Belgium
- Present address: GSK, Wavre, Belgium
| | - K. Green
- Mount Sinai Hospital, Toronto, ON, Canada
| | - S. A. Halperin
- Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, and Nova Scotia Health Authority, Halifax, NS, Canada
| | - T. F. Hatchette
- Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, and Nova Scotia Health Authority, Halifax, NS, Canada
| | - B. Ibarguchi
- GSK, Mississauga, ON, Canada
- Present address: Bayer, Inc., Mississauga, Ontario, Canada
| | - J. Johnstone
- Public Health Ontario and University of Toronto, Toronto, ON, Canada
| | - K. Katz
- North York General Hospital, Toronto, ON, Canada
| | - J. M. Langley
- Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, and Nova Scotia Health Authority, Halifax, NS, Canada
| | | | - M. Loeb
- Public Health Ontario and University of Toronto, Toronto, ON, Canada
| | - A. Lund
- Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, and Nova Scotia Health Authority, Halifax, NS, Canada
| | - D. MacKinnon-Cameron
- Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, and Nova Scotia Health Authority, Halifax, NS, Canada
| | - A. McCarthy
- Ottawa Hospital General, Ottawa, Ontario, Canada
| | - J. E. McElhaney
- Health Sciences North Research Institute, Sudbury, ON, Canada
| | - A. McGeer
- Mount Sinai Hospital, Toronto, ON, Canada
| | - A. Poirier
- Centre Intégré Universitaire de Santé et Services Sociaux, Quebec, QC, Canada
| | - J. Powis
- Toronto East General Hospital, Toronto, ON, Canada
| | | | - M. Semret
- McGill University, Montreal, QC, Canada
| | - V. Shinde
- GSK, King of Prussia, PA, USA
- Present address: Novavax Vaccines, Washington, DC, USA
| | - D. Smyth
- The Moncton Hospital, Moncton, NB, Canada
| | - S. Trottier
- Centre Hospitalier Universitaire de Québec, QC, Canada
| | | | | | - L. Ye
- Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, and Nova Scotia Health Authority, Halifax, NS, Canada
| | - S. A. McNeil
- Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada
| |
Collapse
|
6
|
Shelby T, Banerjee T, Kallu J, Sulthana S, Zegar I, Santra S. Novel magnetic relaxation nanosensors: an unparalleled "spin" on influenza diagnosis. NANOSCALE 2016; 8:19605-19613. [PMID: 27778002 DOI: 10.1039/c6nr05889b] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Rapid detection and diagnosis of pathogenic strains of influenza is necessary for expedited treatment and quicker resolutions to the ever-rising flu pandemics. Considering this, we propose the development of novel magnetic relaxation nanosensors (MRnS) for the rapid detection of influenza through targeted binding with hemagglutinin. 2,6- and 2,3-sialic acid ligands and entry blocker peptides are conjugated to iron oxide nanoparticles to create functional MRnS. Positive detection of various hemagglutinin variants (H1 and H5) is possible with protein concentrations as little as 1.0 nM. Most importantly, detection using functional MRnS is achieved within minutes and differentiates between influenza subtypes. This specificity allows mixtures of MRnS to screen for multiple pathogens at once, discarding the need to conduct multiple individual tests. Current methods used to diagnose influenza, such as RT-PCR and viral culturing, while largely effective, are complex, time-consuming and costly. As well, they are not as sensitive or specific, and have been known to produce false-positive results. In contrast to these methods, targeted MRnS are robust, point-of-care diagnostic tools featuring simple, rapid and low-cost procedures. These qualities, as well as high sensitivity and specificity, and low turnaround times, make a strong case for the diagnostic application of MRnS in clinical settings.
Collapse
Affiliation(s)
- Tyler Shelby
- Department of Chemistry and KPRC, Pittsburg State University, 1701 S. Broadway Street, Pittsburg, KS 66762, USA.
| | - Tuhina Banerjee
- Department of Chemistry and KPRC, Pittsburg State University, 1701 S. Broadway Street, Pittsburg, KS 66762, USA.
| | - Jyothi Kallu
- Department of Chemistry and KPRC, Pittsburg State University, 1701 S. Broadway Street, Pittsburg, KS 66762, USA.
| | - Shoukath Sulthana
- Department of Chemistry and KPRC, Pittsburg State University, 1701 S. Broadway Street, Pittsburg, KS 66762, USA.
| | - Irene Zegar
- Department of Chemistry and KPRC, Pittsburg State University, 1701 S. Broadway Street, Pittsburg, KS 66762, USA.
| | - Santimukul Santra
- Department of Chemistry and KPRC, Pittsburg State University, 1701 S. Broadway Street, Pittsburg, KS 66762, USA.
| |
Collapse
|
7
|
Binkhamis K, Gillis H, Lafreniere JD, Hiebert J, Mendoza L, Pettipas J, Severini A, Hatchette TF, LeBlanc JJ. Comparison of monoplex and duplex RT-PCR assays for the detection of measles virus. J Virol Methods 2016; 239:58-60. [PMID: 27838260 DOI: 10.1016/j.jviromet.2016.11.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2016] [Revised: 11/04/2016] [Accepted: 11/05/2016] [Indexed: 11/25/2022]
Abstract
Rapid and accurate detection of measles virus is important for case diagnosis and public health management. This study compared the performance of two monoplex RT-PCR reactions targeting the H and N genes to a duplex RT-PCR targeting both genes simultaneously. The duplex simplified processing without compromising assay performance characteristic.
Collapse
Affiliation(s)
- Khalifa Binkhamis
- Nova Scotia Health Authority (NSHA) and Dalhousie University, Halifax, NS, Canada
| | - Hayley Gillis
- Nova Scotia Health Authority (NSHA) and Dalhousie University, Halifax, NS, Canada
| | | | - Joanne Hiebert
- Viral Exanthemata and STDs, National Microbiology Laboratory (NML), Public Health Agency of Canada (PHAC), Winnipeg, MB, Canada
| | - Lillian Mendoza
- Viral Exanthemata and STDs, National Microbiology Laboratory (NML), Public Health Agency of Canada (PHAC), Winnipeg, MB, Canada
| | - Janice Pettipas
- Nova Scotia Provincial Public Health Laboratory Network (PPHLN), Halifax, NS, Canada
| | - Alberto Severini
- Viral Exanthemata and STDs, National Microbiology Laboratory (NML), Public Health Agency of Canada (PHAC), Winnipeg, MB, Canada
| | - Todd F Hatchette
- Nova Scotia Health Authority (NSHA) and Dalhousie University, Halifax, NS, Canada
| | - Jason J LeBlanc
- Nova Scotia Health Authority (NSHA) and Dalhousie University, Halifax, NS, Canada.
| |
Collapse
|
8
|
Dorsch M, Meehan B, Michalski WP, Heine HG, Foord AJ, Carlile G, Wang J, McCullough S, Zuelke K. Dual-role FilmArray® diagnostics for high-impact viral diseases. Aust Vet J 2016; 94:64-6. [PMID: 26914951 DOI: 10.1111/avj.12412] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2014] [Revised: 04/13/2015] [Accepted: 10/04/2015] [Indexed: 11/25/2022]
Abstract
In this study, we explored the potential utility of the human-focused FilmArray® Respiratory Panel for the diagnosis of a broad range of influenza viruses of veterinary concern as compared with the standard portfolio of recommended TaqMan®-based diagnostic tests. In addition, we discuss some potential operational advantages associated with the use of such integrated sample extraction, amplification and analysis devices in the context of a future long-term, dual-role strategy for the detection of emergency diseases of both human and veterinary concern.
Collapse
Affiliation(s)
- M Dorsch
- Defence Science and Technology Organisation, Melbourne, Victoria, Australia
| | - B Meehan
- CSIRO, Australian Animal Health Laboratory, Geelong, Victoria, 3220, Australia.
| | - W P Michalski
- CSIRO, Australian Animal Health Laboratory, Geelong, Victoria, 3220, Australia
| | - H G Heine
- CSIRO, Australian Animal Health Laboratory, Geelong, Victoria, 3220, Australia
| | - A J Foord
- CSIRO, Australian Animal Health Laboratory, Geelong, Victoria, 3220, Australia
| | - G Carlile
- CSIRO, Australian Animal Health Laboratory, Geelong, Victoria, 3220, Australia
| | - J Wang
- CSIRO, Australian Animal Health Laboratory, Geelong, Victoria, 3220, Australia
| | - S McCullough
- CSIRO, Australian Animal Health Laboratory, Geelong, Victoria, 3220, Australia
| | - K Zuelke
- CSIRO, Australian Animal Health Laboratory, Geelong, Victoria, 3220, Australia
| |
Collapse
|
9
|
Using Nucleic Acid Amplification Techniques in a Syndrome-Oriented Approach: Detection of Respiratory Agents. Mol Microbiol 2016. [DOI: 10.1128/9781555819071.ch25] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
|
10
|
Shi D, Shen S, Fan X, Chen S, Wang D, Li C, Wu X, Li L, Bai D, Zhang C, Wang J. Evaluation of Commercial Diagnostic Assays for the Specific Detection of Avian Influenza A (H7N9) Virus RNA Using a Quality-Control Panel and Clinical Specimens in China. PLoS One 2015; 10:e0137862. [PMID: 26361351 PMCID: PMC4567293 DOI: 10.1371/journal.pone.0137862] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2015] [Accepted: 08/23/2015] [Indexed: 11/18/2022] Open
Abstract
A novel avian influenza A H7N9-subtype virus emerged in China in 2013 and threatened global public health. Commercial kits that specifically detect avian influenza A (H7N9) virus RNA are urgently required to prepare for the emergence and potential pandemic of this novel influenza virus. The safety and effectiveness of three commercial molecular diagnostic assays were evaluated using a quality-control panel and clinical specimens collected from over 90 patients with confirmed avian influenza A (H7N9) virus infections. The analytical performance evaluation showed that diverse influenza H7N9 viruses can be detected with high within- and between-lot reproducibility and without cross-reactivity to other influenza viruses (H1N1 pdm09, seasonal H1N1, H3N2, H5N1 and influenza B). The detection limit of all the commercial assays was 2.83 Log10 copies/μl [0.7 Log10TCID50/mL of avian influenza A (H7N9) virus strain A/Zhejiang/DTID-ZJU01/2013], which is comparable to the method recommended by the World Health Organization (WHO). In addition, using a WHO-Chinese National Influenza Center (CNIC) method as a reference for clinical evaluation, positive agreement of more than 98% was determined for all of the commercial kits, while negative agreement of more than 99% was observed. In conclusion, our findings provide comprehensive evidence for the high performance of three commercial diagnostic assays and suggest the application of these assays as rapid and effective diagnostic tools for avian influenza A (H7N9) virus in the routine clinical practice of medical laboratories.
Collapse
Affiliation(s)
- Dawei Shi
- Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing, People’s Republic of China
| | - Shu Shen
- Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing, People’s Republic of China
| | - Xingliang Fan
- Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing, People’s Republic of China
- WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, People’s Republic of China
| | - Suhong Chen
- Beijing Institute of Radiation Medicine, Beijing, People’s Republic of China
| | - Dayan Wang
- Chinese National Influenza Center, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People’s Republic of China
- WHO Collaborating Center for Reference and Research on Influenza, Beijing, People’s Republic of China
| | - Changgui Li
- Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing, People’s Republic of China
- WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, People’s Republic of China
| | - Xing Wu
- Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing, People’s Republic of China
- WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, People’s Republic of China
| | - Lili Li
- Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing, People’s Republic of China
| | - Dongting Bai
- Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing, People’s Republic of China
| | - Chuntao Zhang
- Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing, People’s Republic of China
- * E-mail: (CTZ); (JZW)
| | - Junzhi Wang
- Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing, People’s Republic of China
- WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, People’s Republic of China
- * E-mail: (CTZ); (JZW)
| |
Collapse
|
11
|
Pan Y, Peng X, Yang P, Shi W, Cui S, Zhang D, Lu G, Zhao J, Wang Q. Development of an immunomagnetic beads-based test and its application in influenza surveillance. Clin Chem Lab Med 2015; 54:e25-9. [PMID: 26351954 DOI: 10.1515/cclm-2015-0621] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2015] [Accepted: 07/02/2015] [Indexed: 11/15/2022]
|
12
|
Detection of enterovirus D68 in Canadian laboratories. J Clin Microbiol 2015; 53:1748-51. [PMID: 25740765 DOI: 10.1128/jcm.03686-14] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2014] [Accepted: 02/23/2015] [Indexed: 11/20/2022] Open
Abstract
The recent emergence of a severe respiratory disease caused by enterovirus D68 prompted investigation into whether Canadian hospital and provincial laboratories can detect this virus using commercial and laboratory-developed assays. This study demonstrated analytical sensitivity differences between commercial and laboratory-developed assays for the detection of enterovirus D68.
Collapse
|
13
|
Viral lung infections: epidemiology, virology, clinical features, and management of avian influenza A(H7N9). Curr Opin Pulm Med 2015; 20:225-32. [PMID: 24637225 DOI: 10.1097/mcp.0000000000000047] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
PURPOSE OF REVIEW The avian influenza A(H7N9) virus has jumped species barrier and caused severe human infections. Here, we present the virological features relevant to clinical practice, and summarize the epidemiology, clinical findings, diagnosis, treatment, and preventive strategies of A(H7N9) infection. RECENT FINDINGS As of 18 February 2014, A(H7N9) virus has caused 354 infections in mainland China, Taiwan, and Hong Kong with a case-fatality rate of 32%. Elderly men were most affected. Most patients acquired the infection from direct contact with poultry or from a contaminated environment, although person-to-person transmission has likely occurred. A(H7N9) infection has usually presented with severe pneumonia, often complicated by acute respiratory distress syndrome and multiorgan failure. Mild infections have been reported in children and young adults. Nasopharyngeal aspirate and sputum samples should be collected for diagnosis, preferably using reverse transcriptase-PCR. Early treatment with neuraminidase inhibitors improved survival, but the efficacy of antivirals was hampered by resistant mutants. The closure of live poultry markets in affected areas has significantly contributed to the decline in the incidence of human cases. SUMMARY The emergence of A(H7N9) virus represents a significant health threat. High vigilance is necessary so that appropriate treatment can be instituted for the patient and preventive measures can be implemented.
Collapse
|
14
|
Salez N, Nougairede A, Ninove L, Zandotti C, de Lamballerie X, Charrel RN. Xpert Flu for point-of-care diagnosis of human influenza in industrialized countries. Expert Rev Mol Diagn 2014; 14:411-8. [PMID: 24707995 DOI: 10.1586/14737159.2014.901152] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Respiratory infections, particularly those caused by influenza viruses, represent the third-most important cause of death in the world due to infectious diseases. Nevertheless, despite the enormous publicity attracted by epidemics due to these viruses, laboratory diagnosis, documentation and recording of respiratory diseases is still unsatisfactory. Available diagnostic tests capable of providing results rapidly are either limited and insufficiently sensitive or highly sensitive and specific but insufficiently rapid. Considerable investment and research efforts have been made towards the development of new diagnostics for influenza A and B viruses and the Xpert(®) Flu assay (Cepheid(®), CA, USA) has emerged as one of the most promising. In this article, we review current knowledge of the Xpert Flu test, discuss its potential value as a point-of-care test and outline the potential leads for future development.
Collapse
Affiliation(s)
- Nicolas Salez
- Aix Marseille Université, IRD French Institute of Research for Development, EHESP French School of Public Health, EPV UMR_D 190 "Emergence des Pathologies Virales", and IHU Méditerranée Infection, APHM Public Hospitals of Marseille 13385, Marseille, France
| | | | | | | | | | | |
Collapse
|
15
|
Assessment of antigen and molecular tests with serial specimens from a patient with influenza A(H7N9) infection. J Clin Microbiol 2014; 52:2272-4. [PMID: 24671784 DOI: 10.1128/jcm.00446-14] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
|
16
|
|
17
|
Ma MJ, Yang XX, Xia X, Anderson BD, Heil GL, Qian YH, Lu B, Cao WC, Gray GC. Comparison of commercial influenza A virus assays in detecting avian influenza H7N9 among poultry cloacal swabs, China. J Clin Virol 2014; 59:242-5. [PMID: 24529843 DOI: 10.1016/j.jcv.2014.01.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2013] [Revised: 01/12/2014] [Accepted: 01/15/2014] [Indexed: 11/16/2022]
Abstract
BACKGROUND Avian H7N9 virus emerged in China in February 2013 and has since spread widely among China's poultry, causing numerous human infections. OBJECTIVES To compare World Health Organization (WHO) and US commercial influenza assays in detecting avian H7N9 virus in poultry cloacal specimens. STUDY DESIGN Between April 6 and July 15, 2013, 261 cloacal swabs were collected from commercial poultry in Nanjing and Wuxi City, Jiangsu Province, China. Swabs were screened with the WHO's influenza A and H7N9 real-time RT-PCR (qRT-PCR) assays. A blinded panel of 97 specimens (27 H7N9-positive and 70 influenza A-negative) was then used to compare 3 antigen based commercial assays (Remel Xpect Flu A&B, Quidel Quickvue influenza, and Quidel Sofia Influenza A+B), and 2 molecular commercial assays (Quidel Molecular Influenza A+B assay and Life Technologies VetMAX™-Gold SIV Detection Kit). None of these commercial assays were approved for use with poultry specimens. RESULTS Considering the WHO H7N9 qRT-PCR assay as the gold standard, all assays except the Quidel Quickvue influenza assay had high specificity (ranging from 96 to 99%). Regarding sensitivity, the Life Technologies VetMAX™-Gold SIV Detection Kit (100%; 95% CI 87-100%) and the Quidel Molecular Influenza A+B assay (85%; 95% CI 66-96%) performed the best. The sensitivities of the non-molecular antigen detection assays were either unable to detect small amounts of H7N9 viral RNA or were inhibited by specimen type. CONCLUSIONS The Life Technologies VetMAX™-Gold SIV Detection Kit and the Quidel Molecular Influenza A+B assay are comparable in performance to the WHO H7N9 qRT-PCR assay in detecting H7N9 from poultry cloacal specimens.
Collapse
Affiliation(s)
- Mai-Juan Ma
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, PR China
| | - Xiao-Xian Yang
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, PR China
| | - Xian Xia
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, PR China
| | - Benjamin D Anderson
- Department of Environmental & Global Health, College of Public Health & Health Professions, and Emerging Pathogens Institute, University of Florida, Gainesville, FL 32610, USA
| | - Gary L Heil
- Department of Environmental & Global Health, College of Public Health & Health Professions, and Emerging Pathogens Institute, University of Florida, Gainesville, FL 32610, USA
| | - Yan-Hua Qian
- Department of Disease Prevention and Control, Wuxi Center for Disease Control and Prevention, Wuxi 214023, PR China
| | - Bing Lu
- Department of Disease Prevention and Control, Wuxi Center for Disease Control and Prevention, Wuxi 214023, PR China
| | - Wu-Chun Cao
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, PR China.
| | - Gregory C Gray
- Department of Environmental & Global Health, College of Public Health & Health Professions, and Emerging Pathogens Institute, University of Florida, Gainesville, FL 32610, USA.
| |
Collapse
|